Martek Biosciences/Abbott Labs
This article was originally published in The Tan Sheet
Executive Summary
Martek has licensing agreements with manufacturers producing roughly 85% of U.S. and 60% of worldwide infant formula, the firm says, noting it recently signed Abbott Labs as a licensee. The agreement permits Abbott to use Martek's oils containing DHA (docosahexaenoic acid) and ARA (arachidonic acid). However, the inclusion of DHA and ARA in infant formulas in the U.S. remains controversial. Martek awaits an FDA decision on a GRAS notification, filed by the company March 1, for use of DHA and ARA in formulas. If FDA approves the notification, each licensee must obtain authorization from the agency before marketing a DHA- or ARA-containing formula in the U.S
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning